Oncology
Grey Wolf Therapeutics Limited is active in research for solid malignancies, with a focus on antineoplastic therapy and treatment approaches for advanced cancer.
- Advanced malignancies
- Combination cancer therapy
- Immune checkpoint inhibitor combinations
The sponsor’s oncology portfolio reflects interest in therapies designed to address difficult-to-treat malignant disease and support new treatment options in oncology.
Inflammatory and Autoimmune Disease
The company also funds research in axial spondyloarthritis, a chronic inflammatory rheumatic disease affecting the spine and sacroiliac joints.
- Axial spondyloarthritis
- Rheumatology
- Inflammatory disease
This area of interest highlights therapeutic development for immune-mediated conditions with significant impact on mobility, pain, and long-term disease burden.
Targeted Immunotherapy
Grey Wolf Therapeutics Limited’s research includes targeted immunotherapy approaches that seek to modulate disease-relevant pathways in both cancer and immune-mediated disorders.
- ERAP inhibition
- Immune modulation
- Therapeutic combination strategies
Its funded studies indicate sustained interest in therapies that influence immune recognition and disease-specific inflammatory or tumour-related mechanisms.
